Impact of Neoadjuvant Chemotherapy With Gemcitabine Plus Nab-paclitaxel on the Treatment for Borderline Resectable Pancreatic Cancer

被引：0
|
作者：
Miyasaka, Y. [1 ,2 ]
Ohtsuka, T. [1 ]
Kimura, R. [1 ]
Mori, Y. [1 ]
Nakata, K. [1 ]
Nakamura, M. [1 ]
机构：
[1] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Oncol, Fukuoka, Japan
[2] Fukuoka Univ, Dept Surg, Chikushi Hosp, Chikushino, Japan
来源：
PANCREAS | 2019年 / 48卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1492 / 1492
页数：1
相关论文
共 50 条
  • [1] ASO Author Reflections: Impact of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer on Surgical Outcomes
    Miyasaka, Yoshihiro
    Nakamura, Masafumi
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (Suppl 3) : S739 - S740
  • [2] ASO Author Reflections: Impact of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer on Surgical Outcomes
    Yoshihiro Miyasaka
    Masafumi Nakamura
    Annals of Surgical Oncology, 2019, 26 : 739 - 740
  • [3] Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer Potentially Improves Survival and Facilitates Surgery
    Miyasaka, Yoshihiro
    Ohtsuka, Takao
    Kimura, Ryuichiro
    Matsuda, Ryota
    Mori, Yasuhisa
    Nakata, Kohei
    Kakihara, Daisuke
    Fujimori, Nao
    Ohno, Takamasa
    Oda, Yoshinao
    Nakamura, Masafumi
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (05) : 1528 - 1534
  • [4] Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer Potentially Improves Survival and Facilitates Surgery
    Yoshihiro Miyasaka
    Takao Ohtsuka
    Ryuichiro Kimura
    Ryota Matsuda
    Yasuhisa Mori
    Kohei Nakata
    Daisuke Kakihara
    Nao Fujimori
    Takamasa Ohno
    Yoshinao Oda
    Masafumi Nakamura
    Annals of Surgical Oncology, 2019, 26 : 1528 - 1534
  • [5] Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer
    Tsujimoto, Akiko
    Sudo, Kentaro
    Nakamura, Kazuyoshi
    Kita, Emiri
    Hara, Ryusuke
    Takayama, Wataru
    Ishii, Hiroshi
    Yamaguchi, Taketo
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [6] Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer
    Akiko Tsujimoto
    Kentaro Sudo
    Kazuyoshi Nakamura
    Emiri Kita
    Ryusuke Hara
    Wataru Takayama
    Hiroshi Ishii
    Taketo Yamaguchi
    Scientific Reports, 9
  • [7] Phase I Study of Nab-Paclitaxel plus Gemcitabine as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer
    Okada, Ken-Ichi
    Hirono, Seiko
    Kawai, Manabu
    Miyazawa, Motoki
    Shimizu, Atsushi
    Kitahata, Yuji
    Ueno, Masaki
    Hayami, Shinya
    Yamaue, Hiroki
    ANTICANCER RESEARCH, 2017, 37 (02) : 853 - 858
  • [8] A Prospective Study of Neoadjuvant Gemcitabine Plus Nab-paclitaxel in Patients with Borderline-resectable Pancreatic Cancer
    Okano, Naohiro
    Matsuki, Ryota
    Toki, Masao
    Gondo, Koichi
    Ochiai, Kazushige
    Watanabe, Shunsuke
    Tateishi, Hidekatsu
    Kogure, Masaharu
    Suzuki, Yutaka
    Sugiyama, Masanori
    Nagashima, Fumio
    Shibahara, Junji
    Sakamoto, Yoshihiro
    Furuse, Junji
    INTERNAL MEDICINE, 2023, 62 (03) : 327 - 334
  • [9] The clinical impact and analysis for neoadjuvant chemotherapy against borderline resectable pancreatic cancer: Gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel
    Takano, Shigetsugu
    Yoshitomi, Hideyuki
    Kagawa, Shingo
    Furukawa, Katsunori
    Takayashiki, Tsukasa
    Kuboki, Satoshi
    Suzuki, Daisuke
    Sakai, Nozomu
    Mishima, Takashi
    Nakadai, Eri
    Ohtsuka, Masayuki
    CANCER RESEARCH, 2019, 79 (24)
  • [10] A phase I study of preoperative (neoadjuvant) chemotherapy with gemcitabine plus nab-paclitaxel for resectable pancreatic cancer
    Tajima, Hidehiro
    Makino, Isamu
    Gabata, Ryosuke
    Okazaki, Mitsuyoshi
    Ohbatake, Yoshinao
    Shimbashi, Hiroyuki
    Nakanuma, Shinich
    Saitoh, Hiroto
    Shimada, Mari
    Yamaguchi, Takahisa
    Okamoto, Koichi
    Moriyama, Hideki
    Kinoshita, Jun
    Nakamura, Keishi
    Miyashita, Tomoharu
    Ninomiya, Itasu
    Fushida, Sachio
    Ikeda, Hiroko
    Ohta, Tetsuo
    MOLECULAR AND CLINICAL ONCOLOGY, 2021, 14 (02) : 1 - 7
12345